Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belantamab Mafodotin vs Daratumumab with VRd in Newly Diagnosed Multiple Myeloma
NCT07285239Phase 3Recruiting
- Sponsor
- PrECOG
- Start
- Sep 2026
- Primary completion
- Nov 2031
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 3 trial of belantamab mafodotin in multiple myeloma (MM), sponsored by PrECOG. Started Sep 2026; status: recruiting.
02
Drugs
belantamab mafodotin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07285239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07285239.